Skip to main content

Cancer clinical trial eligibility criteria: patients with organ dysfunction or prior or concurrent malignancies

Guidance for Industry

We have adopted this International Scientific Guideline - FDA-2019-D-0359

Last updated

Help us improve this page

This form is anonymous. If you would like a response from us, please visit Contact us.